

a 2022 0008

The invention relates to the field of pharmaceuticals, namely to processes for producing drugs with anti-inflammatory action, intended for the treatment of benign prostatic hyperplasia, associated or not associated with chronic prostatitis. The process for producing an active complex of *Lymantria dispar* larvae, according to the invention, comprises growing of *Lymantria dispar* insects up to the 4th age under controlled conditions on a standardized medium containing, g/kg: wheat flour 80-95, corn flour 82-87, dry vegetable mass 110-120, powdered skimmed milk 2.5-3.5, bee honey 17-19, glycerin 10-12, pinobanksin 0.01-0.02, pinocembrin 0.01-0.02, zinc acetate dihydrate 0.03 -0.05, purified water the rest, freezing of larvae at a temperature of -18°C, washing of larvae, primary grinding, lyophilization, grinding at a temperature of -55°C, packaging and storage of the active complex at a temperature of -18°C.

The technical result of the invention consists in increasing the amount of biomass with higher biological activity and the content of zinc and proteinogenic amino acids, including essential ones.

Claims: 1